39,093 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 39,093 shares of the company's stock, valued at approximately $543,000. Susquehanna Fundamental Investments LLC owned about 0.08% of Tyra Biosciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences during the fourth quarter worth about $56,716,000. Pictet Asset Management Holding SA bought a new stake in Tyra Biosciences in the 4th quarter worth approximately $4,921,000. Investment Counsel Co. of Nevada purchased a new stake in Tyra Biosciences in the fourth quarter worth approximately $1,182,000. Raymond James Financial Inc. bought a new position in Tyra Biosciences during the fourth quarter valued at approximately $761,000. Finally, Marshall Wace LLP lifted its holdings in shares of Tyra Biosciences by 175.7% in the 4th quarter. Marshall Wace LLP now owns 54,077 shares of the company's stock worth $752,000 after acquiring an additional 34,463 shares during the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Stock Down 8.7 %

TYRA traded down $0.87 during midday trading on Wednesday, hitting $9.13. 582,218 shares of the company traded hands, compared to its average volume of 257,565. The company's 50-day moving average is $9.68 and its 200 day moving average is $13.56. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The firm has a market capitalization of $484.71 million, a PE ratio of -5.67 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.